Trial
NCT05921760
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Servier Bio-Innovation LLC
Collaborators
Institut de Recherches Internationales Servier
Condition
IDH1-mutant Cholangiocarcinoma
Intervention
Ivosidenib
Why stopped
The sponsor decided to terminate the study during the safety lead-in phase.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-20